首页 | 本学科首页   官方微博 | 高级检索  
     


HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells
Authors:Curtis R. Pickering PhD  Mitchell J. Frederick PhD  Genevieve A. Andrews MD  Samar A. Jasser PhD  David R. Fooshee BS  Zvonimir L. Milas MD  Chad Galer MD  Daisuke Sano MD  PhD  William N. William MD Jr  Edward Kim MD  John Heymach MD  PhD  Lauren A. Byers MD  Vali Papadimitrakopoulou MD  Jeffrey N. Myers MD  PhD
Affiliation:1. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas;2. Division of Otolaryngology – Head and Neck Surgery, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania;3. Institute for Genomics and Bioinformatics, Department of Information and Computer Sciences, University of California, Irvine, Irvine, California;4. Department of Head and Neck Surgical Oncology, MD Anderson Cancer Center Orlando, Orlando, Florida;5. Richard L Roudebush VAMC/Department of Otolaryngology‐Head and Neck Surgery, Indiana University, Indianapolis, Indiana;6. Department of Biology and Function in Head and Neck, Yokohama City University Graduate School of Medicine, Yokohama, Japan;7. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Abstract:
Keywords:epidermal growth factor receptor  erlotinib  HRAS  resistance  head and neck squamous cell carcinoma
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号